ADMA Biologics, Inc. (ADMA) fair value analysis

Nasdaq · Updated 2026-09-07

ADMA Biologics, Inc. is a biopharmaceutical company that develops and distributes specialty biologics, including plasma-derived therapies and recombinant human proteins used to treat immunodeficiency and other serious conditions. The company operates primarily in the United States, focusing on the manufacturing and commercialization of products for patients with rare and serious diseases.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, ADMA is trading at more than a 25% discount to estimated fair value.

ADMA currently ranks #1 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $8.74
Sector: Healthcare
12-month range: $7.90–$19.38

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: B
Leverage: Low
Margin trend: Expanding
Revenue growth: High
RSI zone: Neutral
50/200-day trend: Downtrend
52-week position: The bottom quarter of its range
DCF cross-check: Overvalued

What our data shows for ADMA

Our model validated 10 trailing price-to-earnings windows for ADMA, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $7.90–$19.38.
The 14-day relative strength index sits at a neutral 55.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for ADMA
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent ADMA news

TickrTrends' derived news-sentiment signal for ADMA is currently leaning positive, computed from recent coverage.

Stonepine Capital Management, LLC Buys Femasys Inc (FEMY) -- Shares Look 70% Undervalued on GF Value (gurufocus.com, 2026-09-04)
TickrTrends take: ADMA operates in the Healthcare sector where valuation discrepancies can present opportunities for investors focused on fundamental analysis. TickrTrends currently assesses ADMA as undervalued, suggesting the market may be pricing in less favorable assumptions than warranted by underlying metrics. In a healthcare landscape where institutional investors like Stonepine Capital are identifying significant valuation gaps in comparable companies, investors monitoring ADMA should track whether similar analytical frameworks reveal analogous pricing inefficiencies in this stock's fundamentals.
ADMA Biologics: Maybe The Bears Are Right (Rating Downgrade) (NASDAQ:ADMA) (seekingalpha.com, 2026-09-02)
TickrTrends take: ADMA Biologics has received a rating downgrade, suggesting analyst skepticism about near-term performance despite TickrTrends' undervalued designation. For valuation-focused investors, this divergence between analyst sentiment and current valuation metrics warrants closer examination of the company's fundamental drivers, particularly given its position in the competitive Healthcare sector. The downgrade introduces uncertainty about whether the undervalued assessment reflects genuine opportunity or misses emerging operational or market challenges that analysts have identified.
Stonepine Capital Management Expands CalciMedica Stake in Bold Contrarian Move (gurufocus.com, 2026-09-01)
TickrTrends take: ADMA Biologics operates in the Healthcare sector where strategic investor moves can signal confidence in underlying asset valuations. Stonepine Capital Management's expansion of its CalciMedica stake represents a contrarian positioning that reflects investor conviction in healthcare opportunities that may not yet be fully recognized by broader markets. For valuation-focused readers tracking ADMA, such moves within the Healthcare investment landscape underscore the importance of monitoring institutional positioning as a potential indicator of whether current market prices adequately reflect future potential.

What people are saying

Follow the ADMA conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — ADMA's momentum indicator downgraded from A to none this week, representing a significant shift in the stock's near-term price movement characteristics. Despite this weakening momentum reading, the stock maintains an undervalued designation based on TickrTrends' derived indicators, suggesting the fundamental valuation metrics remain favorable relative to current pricing within the healthcare sector.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is ADMA stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), ADMA is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is ADMA's TickrTrends verdict?

ADMA's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does ADMA compare to other Healthcare stocks?

ADMA ranks #1 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is ADMA overbought or oversold?

ADMA's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

ADMA vs ALGN · ADMA vs ASTH · ADMA vs AZN · ADMA vs BSX · ADMA vs EMBC